Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boston ScientificBSX -1.87%74 3-1 Month Momentum % is -16.42% as of Aug. 18, 2026. GuruFocus rates BSX with a GF Score™ of 74/100 and a GF Value™ of $106.90 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 849 Medical Devices & Instruments companies, Boston Scientific ranks worse than 67.84% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-18), Boston Scientific's 3-1 Month Momentum % is -16.42%.
The industry rank for Boston Scientific's 3-1 Month Momentum % or its related term are showing as below:
BSX's 3-1 Month Momentum % is ranked worse than 67.84% of 849
companies
in the Medical Devices & Instruments industry
Industry Median: -7.27
vs BSX: -16.42
Boston Scientific (NYSE:BSX) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Boston Scientific 3-1 Month Momentum % Related Terms
BSX vs EW, DXCM, GEHC: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, Boston Scientific's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boston Scientific 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Boston Scientific's 3-1 Month Momentum % falls into.
Boston Scientific (NYSE:BSX) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boston Scientific (BSX) has a 3-1 Month Momentum % of -16.42% as of Aug. 18, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Boston Scientific and its competitors. According to the industry distribution chart, Boston Scientific ranks #576 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 67.8%.
Is Boston Scientific's 3-1 Month Momentum % too high?
Boston Scientific's current 3-1 Month Momentum % is -16.42%. Based on the distribution chart, Boston Scientific ranks #576 out of 849 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Boston Scientific has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Boston Scientific's 3-1 Month Momentum % compare to EW and DXCM?
According to the Medical Devices & Instruments industry distribution chart, Boston Scientific ranks #576 out of 849 companies for 3-1 Month Momentum %. This places Boston Scientific in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Boston Scientific and its competitors. Boston Scientific's current 3-1 Month Momentum % is -16.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boston Scientific stock overvalued right now?
Based on GuruFocus' analysis, Boston Scientific (BSX) is currently considered Significantly Undervalued. The stock's GF Value™ is $106.90, compared to a current price of $50.47 — trading 52.8% below its estimated fair value. The current 3-1 Month Momentum % is -16.42%. Boston Scientific's overall GF Score™ is 74/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Boston Scientific (BSX), the current 3-1 Month Momentum % is -16.42% as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boston Scientific (BSX) Overvalued in 2026?
Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued.
The current stock price of $50.47 is trading 52.8% below its estimated GF Value™ of $106.90.
GuruFocus considers Boston Scientific to be Significantly Undervalued.
Key valuation signals for BSX:
3-1 Month Momentum %: -16.42%
GF Value™: $106.90 vs. price of $50.47 (52.8% below fair value)
No single metric tells the full story. See the BSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
74GF Score
Get the complete analysis for BSX
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSX has been successfully added to your 
